Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Fiche publication
Date publication
janvier 2018
Journal
Current drug targets
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
In the last decade, the introduction of the first anti-tumor necrosis factor (TNF)-α agent infliximab has revolutionized the treatment of ulcerative colitis (UC). However, this drug is not a magic bullet since up to 50% of UC patients do not respond (primary failure) or lose response to infliximab (secondary failure). Hence the demand for novel drugs to fill the unmet medical need.
Mots clés
Anti-integrins, adalimumab, anti-TNF agents, biologic therapy, golimumab, infliximab, ulcerative colitis, vedolizumab.
Référence
Curr Drug Targets. 2018 ;19(7):748-756